Pattern of Clinical Progression Until Metastatic Castration-Resistant Prostate Cancer: An Epidemiological Study from the European Prostate Cancer Registry
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1776-260X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Pattern of Clinical Progression Until Metastatic Castration-Resistant Prostate Cancer: An Epidemiological Study from the European Prostate Cancer Registry ; volume:17 ; number:4 ; day:16 ; month:7 ; year:2022 ; pages:441-451 ; date:7.2022
Targeted oncology ; 17, Heft 4 (16.7.2022), 441-451, 7.2022
- Creator
-
Verry, Camille
Vincendeau, Sébastien
Massetti, Marc
Blachier, Martin
Vimont, Alexandre
Bazil, Marie-Laure
Bernardini, Pauline
Pettré, Ségolène
Timsit, Marc-Olivier
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11523-022-00899-6
- URN
-
urn:nbn:de:101:1-2022101220232614927779
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Verry, Camille
- Vincendeau, Sébastien
- Massetti, Marc
- Blachier, Martin
- Vimont, Alexandre
- Bazil, Marie-Laure
- Bernardini, Pauline
- Pettré, Ségolène
- Timsit, Marc-Olivier
- SpringerLink (Online service)
Other Objects (12)
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Ailanthone: a new potential drug for castration-resistant prostate cancer
Chromogranin A: a useful biomarker in castration-resistant prostate cancer
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Targeting the adaptive molecular landscape of castration‐resistant prostate cancer
Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Ailanthone: a new potential drug for castration-resistant prostate cancer
Chromogranin A: a useful biomarker in castration-resistant prostate cancer
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Targeting the adaptive molecular landscape of castration‐resistant prostate cancer
Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Effect of simvastatin on castration-resistant prostate cancer cells
Ureter metastatic castration-resistant prostate cancer: a case report
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Ailanthone: a new potential drug for castration-resistant prostate cancer
Chromogranin A: a useful biomarker in castration-resistant prostate cancer
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Targeting the adaptive molecular landscape of castration‐resistant prostate cancer